Cromwell Holdings LLC Grows Stock Position in Hologic, Inc. $HOLX

Cromwell Holdings LLC raised its holdings in Hologic, Inc. (NASDAQ:HOLX) by 307.0% in the 2nd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 578 shares of the medical equipment provider’s stock after buying an additional 436 shares during the quarter. Cromwell Holdings LLC’s holdings in Hologic were worth $38,000 at the end of the most recent quarter.

Other institutional investors and hedge funds also recently modified their holdings of the company. Zions Bancorporation National Association UT acquired a new stake in shares of Hologic in the first quarter worth approximately $34,000. Allworth Financial LP raised its stake in Hologic by 46.0% during the first quarter. Allworth Financial LP now owns 686 shares of the medical equipment provider’s stock worth $40,000 after purchasing an additional 216 shares during the period. Bank Julius Baer & Co. Ltd Zurich acquired a new position in shares of Hologic in the 1st quarter valued at $42,000. Larson Financial Group LLC grew its stake in shares of Hologic by 6,016.7% during the 1st quarter. Larson Financial Group LLC now owns 734 shares of the medical equipment provider’s stock valued at $45,000 after buying an additional 722 shares during the period. Finally, Hanson & Doremus Investment Management acquired a new stake in shares of Hologic during the 1st quarter worth $99,000. Institutional investors and hedge funds own 94.73% of the company’s stock.

Analyst Upgrades and Downgrades

A number of research analysts recently weighed in on the company. Citigroup upgraded Hologic from a “neutral” rating to a “buy” rating and lifted their target price for the company from $60.00 to $80.00 in a report on Wednesday, July 9th. Morgan Stanley boosted their target price on Hologic from $65.00 to $69.00 and gave the stock an “equal weight” rating in a report on Thursday, July 31st. Mizuho set a $75.00 target price on shares of Hologic in a research report on Thursday, July 31st. Weiss Ratings reaffirmed a “hold (c-)” rating on shares of Hologic in a research report on Saturday, September 27th. Finally, Stephens reissued an “overweight” rating and issued a $78.00 price objective on shares of Hologic in a research report on Thursday, September 18th. One analyst has rated the stock with a Strong Buy rating, eight have issued a Buy rating and nine have assigned a Hold rating to the stock. According to MarketBeat, Hologic presently has a consensus rating of “Moderate Buy” and an average price target of $79.38.

Hologic Trading Up 0.5%

NASDAQ HOLX opened at $68.22 on Friday. The stock has a market cap of $15.17 billion, a P/E ratio of 28.31, a PEG ratio of 2.33 and a beta of 0.63. The company’s fifty day simple moving average is $66.97 and its 200-day simple moving average is $63.08. The company has a current ratio of 3.55, a quick ratio of 2.81 and a debt-to-equity ratio of 0.52. Hologic, Inc. has a 52 week low of $51.90 and a 52 week high of $84.39.

Hologic (NASDAQ:HOLX) last released its quarterly earnings results on Wednesday, July 30th. The medical equipment provider reported $1.08 earnings per share for the quarter, beating analysts’ consensus estimates of $1.05 by $0.03. Hologic had a net margin of 13.79% and a return on equity of 19.69%. The business had revenue of $1.02 billion during the quarter, compared to analyst estimates of $1.01 billion. During the same period last year, the business earned $1.06 EPS. The business’s revenue was up 1.2% on a year-over-year basis. Hologic has set its Q4 2025 guidance at 1.090-1.120 EPS. FY 2025 guidance at 4.230-4.260 EPS. Equities research analysts predict that Hologic, Inc. will post 4.28 EPS for the current fiscal year.

Insider Activity at Hologic

In related news, CEO Stephen P. Macmillan sold 138,358 shares of the stock in a transaction dated Monday, September 22nd. The stock was sold at an average price of $66.97, for a total value of $9,265,835.26. Following the completion of the transaction, the chief executive officer owned 1,234,624 shares of the company’s stock, valued at approximately $82,682,769.28. This represents a 10.08% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through this link. Company insiders own 1.88% of the company’s stock.

About Hologic

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.